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OBJECTIVES We sought to determine the safety and efficacy of using multiple overlapping drug-eluting
stents (DES) in patients with diffuse left anterior descending coronary artery (LAD) disease.
BACKGROUND Diffuse LAD disease represents a therapeutic challenge. Results after coronary artery bypass
surgery are suboptimal, whereas the use of bare metal stents is limited by high rates of
restenosis. The introduction of DES prompted treatment of long diffuse disease with multiple
overlapping stents.
METHODS All consecutive patients with de novo diffuse LAD disease treated with more than 60-mm
long DES from April 2002 to March 2004 were analyzed.
RESULTS The study population consisted of 66 patients. Thirty-nine patients were treated with sirolimus-
eluting stents (SES), average length 84  22 mm, and 27 patients with paclitaxel-eluting stents
(PES), average length 74  14 mm. The number of stents implanted per patient was 2.8  0.7,
whereas the mean total stent length for the LAD treatment was 80  20 mm. Angiographic as
well as procedural success was achieved in 95% of cases. Eleven (16.6%) patients had in-hospital
non–Q-wave myocardial infarction (five SES and six PES), and one patient developed intrapro-
cedural stent thrombosis. All patients had clinical follow-up, and 52 patients (79%) had an
angiographic follow-up at six months. Hierarchical major adverse cardiac event rate was 15%
(7.5% for SES and 7.5% for PES). No patients died, one patient had non–Q-wave myocardial
infarction (non-index vessel), and 10 patients (15%) underwent target vessel revascularization.
CONCLUSIONS The implantation of multiple overlapping DES in patients with a diffusely diseased LAD is
relatively safe and associated with good midterm clinical outcomes. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.0492005;45:1570–3) © 2005 by the American College of Cardiology Foundation
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iiffuse coronary artery disease poses a significant therapeu-
ic challenge. In 25% of these patients, coronary artery
ypass grafting (CABG) cannot be safely performed, and
he condition often is deemed inoperable (1). Furthermore,
n many of these cases, complete revascularization and
dequate myocardial perfusion cannot be achieved with
ABG. Alternative revascularization procedures (2–4) of-
en are undertaken, with suboptimal results.
The percutaneous implantation of bare-metal stents (BMS)
s associated with high rates of restenosis (5–7). The use of
rug-eluting stents (DES) has greatly attenuated the relation-
hip between stent length and restenosis (8–10). The aim of
he present study was to evaluate the safety and efficacy of using
ultiple overlapping DES to treat patients with diffuse left
nterior descending coronary artery (LAD) disease.
ETHODS
atient population and procedures. Patients with diffuse
e novo LAD disease undergoing implantation of minimum
f 60-mm long sirolimus-eluting stents (SES) (Cypher,
From the *San Raffaele Hospital and †Columbus Hospital, Milan, Italy.L
Manuscript received November 24, 2004; revised manuscript received January 18,
005, accepted January 25, 2005.ordis/Johnson & Johnson, Warren, New Jersey) or
aclitaxel-eluting stents (PES) (Taxus, Boston Scientific,
atick, Massachusetts) between April 2002 and May 2004
omposed the study population. Each patient signed an
nformed consent form. The implantation of DES was
erformed following the practice of fully covering the
iseased segment. All patients had a combination of at least
wo overlapping stents (overlapping segment approximately
to 4 mm) in the LAD, with total stent length 60 mm.
he reported stented length is based on the cumulative
ength of the adjacent stents. Heparin was administered at
he beginning of the procedure at the dose of 100 IU/kg to
chieve an activated clotting time 250 s. Glycoprotein
GP) IIb/IIIa inhibitors were administered at the discretion
f the operator.
All patients received aspirin (at least 100 mg once daily)
nd clopidogrel 75 mg once daily or ticlopidine 250 mg
wice daily at least three days before the procedure, with a
oading dose of 300 mg of clopidogrel to patients not
retreated. Thienopyridines were continued for at least
hree months after the procedure.
ngiographic analysis. Cineangiograms were analyzed us-
ng a validated edge system (CMS, version 5.2, MEDIS,
eiden, the Netherlands). Angiographic success was defined
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May 17, 2005:1570–3 Diffuse LAD Disease Treated With DESs Thrombolysis In Myocardial Infarction (TIMI) flow
rade 3 and 30% residual diameter stenosis by visual
ssessment. Restenosis was defined as 50% diameter
tenosis by qualitative coronary angiography within a pre-
iously stented segment. Angiography was scheduled at six
onths or earlier if clinically indicated.
linical follow-up. Clinical follow-up was performed by
ither telephone contact or office visit. All patients were
valuated for the occurrence of major cardiac events
MACE), a composite end point comprising death, myo-
ardial infarction (MI), and target vessel revascularization.
diagnosis of non–Q-wave MI was made when there was
n increase of creatine kinase two times the upper limit of
ormal accompanied by increased values of creatine kinase-
yocardial band. Diagnosis of Q-wave MI was made when
evelopment of new abnormal Q waves, not present in
aseline electrocardiogram, also occurred. Intraprocedural
tent thrombosis was defined as an angiographically con-
able 1. Baseline Clinical and Procedural Characteristics
n  66)
ge, yrs 62  9.6
en, n (%) 61 (92)
VEF, % 50  11.5
ypercholesterolemia, n (%) 52 (79)
ypertension, n (%) 46 (70)
iabetes mellitus, n (%) 19 (29)
revious MI, n (%) 30 (45)
revious PCI, n (%) 18 (27)
revious CABG, n (%) 8 (12)
ngina type, n (%)
Silent ischemia 27 (41)
Stable 20 (30)
Unstable 19 (29)
1 vessel treated, n (%) 51 (77)
oncomitant bifurcation treatment on the side
branch, n (%)
35 (53)
Balloon angioplasty, n 13
DES, n 22
lycoprotein IIb/IIIa inhibitors, n (%) 31 (47)
eference vessel diameter, mm 2.53  0.6
ean diameter of DES stent, mm 2.8  0.7
ean length of lesion, mm 64  18
ean length of DES per lesion, mm 80  20
ean number of DES per lesion, mm 2.8  0.7
ABG  coronary artery bypass grafting; DES  drug-eluting stents; LVEF  left
Abbreviations and Acronyms
BMS  bare-metal stent
CABG  coronary artery bypass grafting
DES  drug-eluting stents
GP  glycoprotein
LAD  left anterior descending coronary artery
MACE major adverse cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
TIMI  Thrombolysis In Myocardial Infarctionp
entricular ejection fraction; MI  myocardial infarction; PCI  percutaneous
oronary intervention.rmed intraluminal filling defect within the stent resulting
n TIMI anterograde flow grade 0 or 1 that occurred during
he procedure. Postprocedural stent thrombosis was defined
s any of the following between the end of the procedure
nd the end of follow-up: angiographic documentation of
tent occlusion, unexplained sudden death when the stent
as not known to be patent, or MI or urgent target lesion
evascularization occurring in the territory of the LAD.
arget vessel revascularization was defined as revasculariza-
ion driven by significant luminal narrowing (50%) within
he stent or within the 5-mm borders proximal and distal to
he stent.
tatistical analysis. Discrete variables are presented as
ercentages and continuous variables as mean values  SD.
he Student paired t test was used to identify changes over
ime in the same patients, whereas the Kaplan-Meier
ethod was used to analyze the occurrence of the composite
nd point of MACE during follow-up.
ESULTS
mmediate results. Baseline clinical and procedural char-
cteristics are presented in Table 1. Diabetes mellitus was
resent in 19 patients (29%), and 19 (29%) had unstable
ngina. Ten patients had an ejection fraction 40%, and
oronary bypass surgery had been performed previously in
ight (12%). Chronic total occlusions were present in 13
20%) patients. The lesion length per vessel was 64  18
m and reference vessel diameter was 2.53  0.6 mm.
Thirty-nine patients were treated with SES (average
ength, 84  22 mm) and 27 patients with PES (average
ength, 74 14 mm). Angiographic success was achieved in
5% of the patients treated. Three patients had TIMI flow
rade 2 at the end of the procedure. Directional atherec-
omy was performed in five patients, rotational atherectomy
n one patient, and cutting balloon in seven patients. The
umber of stents implanted per lesion was 2.8 0.7 (range,
to 4 stents), and the diameter of the stents was 2.8  0.7
m. Thirty-five patients (53%) received bifurcation treat-
ent of diagonal branches: balloon angioplasty of the side
ranch was performed in 13 patients, and DES implanta-
ion was performed in the remaining patients (SES in 15
able 2. Quantitative Coronary Angiographic Analysis at
aseline, After Procedure, and at Six-Month Angiographic
ollow-Up (n  52)
Baseline
After
Procedure
Six-Month
Follow-up
VD, mm 2.43  0.6 2.86  0.48 2.88  0.56
LD, mm 0.76  0.5 2.54  0.5 2.22  0.86
ercent diameter
stenosis
68.5  19.3 11.4  7.8 24.2  22.8
ate lumen loss, mm 0.44  0.77
estenosis rate 19.6%
LD  minimal luminal diameter; RVD  reference vessel diameter.atients and PES in 7 patients). Glycoprotein IIb/IIIa
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Diffuse LAD Disease Treated With DES May 17, 2005:1570–3nhibitors were administered electively in 31 patients (47%).
ntraprocedural thrombosis occurred in one patient. Eleven
atients (16.6%) developed periprocedural non–Q-wave MI
five with SES and six with PES). No patient developed
-wave MI or died during hospitalization.
idterm outcome. Follow-up coronary angiography was
erformed in 52 patients (79%; Table 2). Binary restenosis
n the LAD occurred in 10 (19.6%) patients (5 SES, 5
ES). Most (70%) restenotic lesions were focal (10 mm in
ength), single in five patients, and multifocal in two
atients (Fig. 1). In one of the patients (PES), the restenosis
as diffuse and occurred in the vessel segment proximal to
he stent. A second patient, originally treated for chronic
otal LAD occlusion with SES implantation, developed
cclusive restenosis.
Among the patients who had concomitant treatment of
iagonal branches, five patients developed restenosis at the
stium of the branch. All patients who did not undergo
ollow-up coronary angiography were asymptomatic and
nderwent exercise testing, which was negative for ischemia.
Clinical follow-up was available for all patients, and all
ollow-up extended at least six months. At an average period
f 13.6  6.5 months, there were no deaths, no stent
hrombosis, and no Q-wave MI (Table 3). One patient
xperienced non–Q-wave MI one month after the proce-
ure and underwent emergency percutaneous revasculariza-
ion of the obtuse marginal branch. Ten patients (15%)
nderwent target vessel revascularization. The Kaplan-
eier estimated probability of cumulative MACE-free
igure 1. Diffuse disease of the left anterior descending coronary artery (A
onths with focal in-stent restenosis is shown (C).urvival was 71.21% (Fig. 2). Thienopyridine therapy was
C
viscontinued in 28 patients (42.4%) after an average period
f 9  4.6 months (range, 3 to 18 months).
ISCUSSION
his study is the first to report that percutaneous treatment
f diffuse LAD disease with multiple overlapping DES
total length 60 mm) is feasible, apparently safe, and
ssociated with acceptable rates of MACE in the midterm
ollow-up. The implantation of multiple overlapping BMS
s associated with high restenosis rates (5–7). The use of
hort stents (spot stenting) with intravascular ultrasound
uidance (11) was proposed as an alternative strategy, but
his technique is laborious.
Percutaneous treatment of LAD lesions with SES has
een reported to result in revascularization rates comparable
ith historic single-vessel CABG revascularization rates
9). Data concerning the implantation of multiple over-
apping DES in patients with diffusely diseased LAD are
ted with three sirolimus-eluting stents (B). Angiographic follow-up at six
able 3. Major Adverse Cardiac Events During Hospitalization
nd at Follow-Up
Characteristics
In Hospital
(n  66)
Follow-Up
(n  66)
eath 0 0
-wave MI 0 0
on–Q-wave MI 11 (16.6%) 1 (1.5%)
hrombosis 1 (1.5%) 0
VR 0 10 (15%)
ABG 0 1 (1.5%)ABG coronary artery bypass grafting; MImyocardial infarction; TVR target
essel revascularization.
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May 17, 2005:1570–3 Diffuse LAD Disease Treated With DESacking. In our study, the mean stent length was 80 mm
range, 61 to 120 mm), that is, at least 20 mm longer than
n previously reported series with DES (10) and 30 mm
onger than the reported series with BMS .
Concerns exist about the increased probability of stent
hrombosis (12) using very long stents; however, in our
tudy only one patient developed intraprocedural stent
hrombosis (with immediate resolution of the thrombus
fter GP IIb/IIIa inhibitor administration). No late throm-
osis occurred.
The risk of compromising the flow in the numerous
iagonal and septal branches originating from the LAD
epresents a valid concern. This fact may explain the high
ncidence of non–Q-wave MI compared with other studies
10). A more liberal administration of GP IIb/IIIa inhibi-
ors (given to 47% of the patients and in 5 of 11 patients
ho sustained MI) could have reduced the incidence of
yocardial infarction, but other factors may be implied.
A 19.6% incidence of restenosis is an area in which
mprovement is needed. A positive aspect, consistent with
revious reports evaluating the mode of failure of DES (13),
s that the angiographic pattern of restenosis in most of the
estenotic lesions was focal. With the exception of one
atient, who underwent CABG in another hospital, repeat
ercutaneous intervention was the mode of treatment for
he rest of the patient population that developed restenosis.
tudy limitations. The main limitation of this study is the
igure 2. Kaplan-Meier estimates of cumulative survival free from major
dverse cardiac events (continuous line) and free from death and myocar-
ial infarction (dotted line).ack of a control group treated with CABG or with medicalherapy. The relative small number of patients included and
he short follow-up time are other important shortcomings.
longer follow-up time is needed to evaluate any possible
isk of late thrombosis, and uncertainties are present regard-
ng the optimal duration of double antiplatelet therapy.
onclusions. Implantation of multiple long overlapping
ES in patients with diffuse LAD disease is relatively safe
nd is associated with good midterm clinical outcomes.
eprint requests and correspondence: Dr. Antonio Colombo,
MO Centro Cuore Columbus, Via M. Buonarrotti 48, 20145
ilan, Italy. E-mail: info@emocolumbus.it.
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